Skip to main content

Table 3 Plasma and CSF NfL and YKL-40 levels

From: Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease

Plasma NfL (pg/mL)

Plasma YKL-40 (ng/mL)

CSF YKL-40 (ng/mL)

Whole cohort (n = 123)

18.53 (6.98–216.57)

Whole cohort (n = 125)

45.1 (8.4–355.1)

Whole cohort (n = 120)

272.3 (102.4–538.7)

Controls (n = 39)

17.03 (6.98–216.57)

Controls (n = 39)

44.9 (13.0–316.3)

Controls (n = 37)

307.1 (102.4–506.1)

MCI-MCI (n = 29)

17.60 (7.34–45.82)

MCI-MCI (n = 30)

49.7 (8.4–168.7)

MCI-MCI (n = 28)

233.6 (126.9–507.2)

MCI-ADD (n = 27)

19.57 (7.59–42.38)

MCI-ADD (n = 28)

44.9 (16.3–248.4)

MCI-ADD (n = 28)

307.8 (156.2–538.7)

ADD (n = 28)

20.81 (12.61–94.97)*, #

ADD (n = 28)

45.4 (15.8–355.1)

ADD (n = 27)

260.2 (161.4–519.4)

p-value

0.008a

p-value

nsb

p-value

nsc

  1. Results are presented as median (minimum–maximum). MCI-MCI patients with amnestic mild cognitive impairment that did not progress to an ADD diagnosis during the study period, MCI-ADD patients with amnestic mild cognitive impairment that fulfilled the ADD diagnostic criteria after two years, ADD patients with Alzheimer’s disease with dementia at baseline, NfL: Neurofilament light chain, ns Non-significant, a Quade nonparametric ANCOVA, b Kruskal–Wallis, c ANCOVA with age as covariant
  2. *,#: p ≤ 0.05 corresponds to pairwise comparison between ADD patients and controls (*) or MCI-MCI (#) corrected for multiple comparisons (n = 6)